title: CYP2E1 T7632A and 9-bp insertion polymorphisms and colorectal cancer risk: a meta-analysis based on 4,592 cases and 5,918 controls.
abstract: Previous studies suggest that genetic factors play important roles in the development of colorectal cancer. CYP2E1 T7632A and 9-bp insertion polymorphisms may influence the risk of colorectal cancer, but published results are conflicting. We therefore conducted a meta-analysis comprising 9 case-control studies with 4,592 cases and 5,918 controls. Odds ratios (ORs) with 95 % confidence interval (95 % CI) were used to assess the strength of the associations of CYP2E1 T7632A and 9-bp insertion polymorphisms with colorectal cancer. For CYP2E1 T7632A polymorphism, meta-analysis showed that there was no significant association between the CYP2E1 T7632A polymorphism and colorectal cancer risk under all contrast models (A vs. T: OR = 1.06, 95 % CI 0.88-1.29, P = 0.528; AA vs. TT: OR = 0.85, 95 % CI 0.61-1.19, P = 0.351; AA/TA vs. TT: OR = 1.08, 95 % CI 0.87-1.34, P = 0.484; and AA vs.
  OR = 0.87, 95 % CI 0.62-1.21, P = 0.395). For CYP2E1 96-bp insertion polymorphism, meta-analysis showed that there was a significant association between the CYP2E1 96-bp insertion polymorphism and colorectal cancer risk under the allele contrast model and the dominant contrast model (for the allele contrast model: OR = 1.20, 95 % CI 1.06-1.36, P = 0.005; for the dominant contrast model: OR = 1.25, 95 % CI 1.07-1.45, P = 0.005). Subgroup analysis by race suggested that there was an obvious association between the CYP2E1 96-bp insertion polymorphism and colorectal cancer risk in Asians under the codominant contrast model. In conclusion, our meta-analysis demonstrates that there is a significant association between the CYP2E1 96-bp insertion polymorphism and colorectal cancer risk, and CYP2E1 9-bp insertion polymorphism is a risk factor for developing colorectal cancer.
authors: Department of Colorectal Surgery, Xinchang People's Hospital, Zhejiang Province, Xinchang, 312500, China.
authors: Jun
authors: J
authors: Qian
authors: Zhangfa
authors: Z
authors: Song
authors: Yinxiang
authors: Y
authors: Lv
authors: Xuefeng
authors: X
authors: Huang
mesh_terms: D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000235:genetics*; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D016254:Mutagenesis, Insertional; D011110:Polymorphism, Genetic; D012306:Risk
chemical_list: D019392:Cytochrome P-450 CYP2E1
references: Mutat Res. 2006 Jan 29;593(1-2):39-49
references: 16039674
references: Carcinogenesis. 2007 Jan;28(1):101-6
references: 16837478
references: Tumour Biol. 2012 Aug;33(4):979-84
references: 22249978
references: Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1019-24
references: 12376502
references: Lancet. 2010 Mar 20;375(9719):1030-47
references: 20304247
references: PLoS One. 2012;7(7):e40883
references: 22815852
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Am J Epidemiol. 2010 Nov 1;172(9):1000-14
references: 20937634
references: PLoS One. 2012;7(11):e48265
references: 23139769
references: Tumour Biol. 2013 Feb;34(1):555-63
references: 23188703
references: Genet Test Mol Biomarkers. 2011 Jun;15(6):423-9
references: 21385088
references: Drug Metab Pharmacokinet. 2012;27(1):68-84
references: 22041138
references: CA Cancer J Clin. 2009 Nov-Dec;59(6):366-78
references: 19897840
references: Eur J Cancer. 2010 Mar;46(4):758-64
references: 20031389
references: Annu Rev Pharmacol Toxicol. 2004;44:27-42
references: 14744237
references: Genet Mol Res. 2012 Sep 03;11(3):3138-45
references: 23007992
references: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):235-41
references: 19124503
references: Annu Rev Pathol. 2011;6:479-507
references: 21090969
references: J Toxicol Environ Health B Crit Rev. 2009;12(5-6):362-88
references: 20183527
references: Adv Pharmacol. 2012;63:137-67
references: 22776641
references: Mol Biol Rep. 2012 Jan;39(1):607-12
references: 21553050
references: PLoS One. 2012;7(5):e34809
references: 22606226
references: Med Oncol. 2011 Mar;28(1):182-7
references: 20195803
references: Hum Genomics. 2011 Oct;5(6):530-7
references: 22155602
references: Drug Metab Rev. 2004 May;36(2):313-33
references: 15237857
references: N Engl J Med. 2009 Dec 17;361(25):2449-60
references: 20018966
references: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3098-107
references: 18990750
references: J Cancer Epidemiol. 2012;2012:952508
references: 23125859